GlassScriptPhysician profile
Amanda J Winters
NPI 1003020496
$13,297.22
in general payments reported to CMS, 2019-2025
18 companies · $11K in 2025
The $11K reported for 2025 was more than what 97% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $732 · 2021: $14.88 · 2022: $17.95 · 2023: $220 · 2024: $41.99 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,855 · Travel and Lodging: $1,676 · Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,855.00 |
| Travel and Lodging | $1,675.85 |
| Food and Beverage | $671.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $10,940.16 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $540.69 | 2019-2021 | |
| Alkermes, INC. | $521.56 | 2019-2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $346.48 | 2019-2024 | Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $321.34 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $227.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.15 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $67.91 | 2019-2020 | |
| Allergan, INC. | $65.95 | 2019-2020 | |
| Shire North American Group INC | $32.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.24 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $26.54 | 2019 | |
| Acadia Pharmaceuticals INC | $22.72 | 2019 | |
| Neuronetics, INC. | $16.52 | 2019 | |
| Eisai INC. | $16.16 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.96 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.38 | 2020 | |
| Vanda Pharmaceuticals INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.